Stay updated with breaking news from Recurrence Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Breast Cancer Index is the only genomic test that should be used to guide extended endocrine therapy decisions for women with early-stage, hormone receptor–positive breast cancer, says ASCO.
Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant
PALM BEACH, Fla., May 4, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over
Oncotype DX receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast...